Sign inJoin waitlistJoin the waitlist

AT

Ana Tergas

Assistant Professor - Gyn Oncology Division Director · Rutgers Health

Credentials: · · · · · · · ·

History

Rutgers Health
Present

Gynecologic Oncology
Johns Hopkins University School of Medicine
2017–2020
Infectious Disease
SUNY Downstate Health Sciences University
2016–2017
SSM Health/Saint Louis University School of Medicine
2013–2015
Obstetrics and Gynecology
University of Chicago Medical Center
2006–2010
Leonard M. Miller School of Medicine
2002–2006

Research

Prognostic Performance of the 2018 International Federation of Gynecology and Obstetrics Cervical Cancer Staging Guidelines
Obstetrics and Gynecology · 2019 · 235 citations
Survival After Minimally Invasive vs Open Radical Hysterectomy for Early-Stage Cervical Cancer: A Systematic Review and Meta-analysis
Systematic review or meta-analysis · JAMA Oncology · 2020 · 159 citations
Night-shift work and risk of breast cancer: a systematic review and meta-analysis
Systematic review or meta-analysis · Breast Cancer Research and Treatment · 2013 · 142 citations

Jason Wright
116 papers
June Hou
97 papers
Dawn Hershman
93 papers
Alfred Neugut
74 papers
William Burke
56 papers
Caryn Clair
41 papers
Fady Collado
33 papers
Alexander Melamed
31 papers · 17 as a fellow
Jim Hu
14 papers
Melissa Accordino
10 papers
Allison Gockley
9 papers · 8 as a fellow
Sudeshna Chatterjee
9 papers · 9 as a fellow

Grants

Impact of the Therapeutic Alliance on Reduction of Disparities in Latino End-of-Life Cancer Care
National Cancer Institute · K08
Contact PI · $1.2M · Rutgers Biomedical and Health Sciences
2020–2026

Clinical trials

HOLA Intervention Pilot
Principal investigator · Enrolling by invitation
Rutgers, The State University of New Jersey
2026
Mail-in HPV Screening Program in NJ
Principal investigator · Enrolling by invitation
Rutgers, The State University of New Jersey
2026–2027
Impact of the Therapeutic Alliance on Reduction of Disparities in Latino End-of-Life Cancer Care
Principal investigator · Completed
City of Hope Medical Center
2023–2024
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2025–2030